Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (897 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Ichthyoses; Xeroderma; Xerodermas.
Where it fits in the MeSH classification
- Broader topics
- Skin Abnormalities; Infant, Newborn, Diseases; Keratosis
- Narrower topics
- Ichthyosiform Erythroderma, Congenital; Ichthyosis Bullosa of Siemens; Ichthyosis Vulgaris; Ichthyosis, X-Linked; Sjogren-Larsson Syndrome
Research landscape
PubMed indexes 6,172 records tagged with the MeSH heading “Ichthyosis” (counts retrieved 2026-10-29). 825 of them (13.4%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,786 records.
Reviews account for 721 records (11.7%) and meta-analyses for 3. Randomized controlled trials number 42 (0.7%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 2,786 |
| 2000-2009 | 1,056 |
| 2010-2019 | 1,505 |
| 2020 onward | 825 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 721 | 11.7% |
| Meta-analyses | 3 | 0.0% |
| Randomized controlled trials | 42 | 0.7% |
Method: PubMed query "Ichthyosis"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in rare and inherited diseases
Rare conditions are difficult to study: few patients means small studies, case reports and registries are common, and randomized trials are the exception. Small samples limit precision and can exaggerate effects, and cases reported in the literature may be the most severe or unusual. Evidence from many small studies is best read together. Check how patients were identified, how many were included and how long they were followed.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome | 2020 | Research article Design not recorded in structured metadata | 91 | cc by PMID 32130897 · DOI · PMC7183042 |
| KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome | 2015 | Research article Design not recorded in structured metadata | 77 | cc by PMID 26390218 · DOI · PMC4577096 |
| KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype | 2017 | Research article Design not recorded in structured metadata | 74 | cc by PMID 28095415 · DOI · PMC5283769 |
| Physiological and Behavioural Characterisation of a Novel Steroid Sulfatase-Deficient Mouse | 2026 | Research article Design not recorded in structured metadata | 1 | cc by PMID 42449517 · DOI · PMC13369296 |
Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Netherton syndrome (NS) is a monogenic skin disease resulting from loss of function of lymphoepithelial Kazal-type-related protease inhibitor (LEKTI-1).
- Closing excerpt
- These findings demonstrate the critical need for maintaining homeostasis of host and microbial proteases to prevent a human skin disease.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (155 words)
Netherton syndrome (NS) is a monogenic skin disease resulting from loss of function of lymphoepithelial Kazal-type-related protease inhibitor (LEKTI-1). In this study we examine if bacteria residing on the skin are influenced by the loss of LEKTI-1 and if interaction between this human gene and resident bacteria contributes to skin disease. Shotgun sequencing of the skin microbiome demonstrates that lesional skin of NS subjects is dominated by Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis). Isolates of either species from NS subjects are able to induce skin inflammation and barrier damage on mice. These microbes promote skin inflammation in the setting of LEKTI-1 deficiency due to excess proteolytic activity promoted by S. aureus phenol-soluble modulin α as well as increased bacterial proteases staphopain A and B from S. aureus or EcpA from S. epidermidis. These findings demonstrate the critical need for maintaining homeostasis of host and microbial proteases to prevent a human skin disease.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32130897 · DOI · PMC7183042
KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Netherton Syndrome (NS) is a rare and severe autosomal recessive skin disease which can be life-threatening in infants.
- Closing excerpt
- These findings illustrate the crucial role of protease regulation in skin homeostasis and inflammation, and establish KLK5 inhibition as a major therapeutic target for NS.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (297 words)
Netherton Syndrome (NS) is a rare and severe autosomal recessive skin disease which can be life-threatening in infants. The disease is characterized by extensive skin desquamation, inflammation, allergic manifestations and hair shaft defects. NS is caused by loss-of-function mutations in SPINK5 encoding the LEKTI serine protease inhibitor. LEKTI deficiency results in unopposed activities of kallikrein-related peptidases (KLKs) and aberrantly increased proteolysis in the epidermis. Spink5⁻/⁻ mice recapitulate the NS phenotype, display enhanced epidermal Klk5 and Klk7 protease activities and die within a few hours after birth because of a severe skin barrier defect. However the contribution of these various proteases in the physiopathology remains to be determined. In this study, we developed a new murine model in which Klk5 and Spink5 were both knocked out to assess whether Klk5 deletion is sufficient to reverse the NS phenotype in Spink5⁻/⁻ mice. By repeated intercrossing between Klk5⁻/⁻ mice with Spink5⁻/⁻ mice, we generated Spink5⁻/⁻Klk5⁻/⁻ animals. We showed that Klk5 knock-out in Lekti-deficient newborn mice rescues neonatal lethality, reverses the severe skin barrier defect, restores epidermal structure and prevents skin inflammation. Specifically, using in situ zymography and specific protease substrates, we showed that Klk5 knockout reduced epidermal proteolytic activity, particularly its downstream targets proteases KLK7, KLK14 and ELA2. By immunostaining, western blot, histology and electron microscopy analyses, we provide evidence that desmosomes and corneodesmosomes remain intact and that epidermal differentiation is restored in Spink5⁻/⁻Klk5⁻/⁻. Quantitative RT-PCR analyses and immunostainings revealed absence of inflammation and allergy in Spink5⁻/⁻Klk5⁻/⁻ skin. Notably, Il-1β, Il17A and Tslp levels were normalized. Our results provide in vivo evidence that KLK5 knockout is sufficient to reverse NS-like symptoms manifested in Spink5⁻/⁻ skin. These findings illustrate the crucial role of protease regulation in skin homeostasis and inflammation, and establish KLK5 inhibition as a major therapeutic target for NS.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26390218 · DOI · PMC4577096
KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Netherton syndrome (NS) is a severe skin disease caused by the loss of protease inhibitor LEKTI, which leads to the dysregulation of epidermal proteases and severe skin-barrier defects.
- Closing excerpt
- Altogether, these findings show that unregulated activities of KLK5 and KLK7 are responsible for NS development and both proteases should become targets for NS therapy.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)
Netherton syndrome (NS) is a severe skin disease caused by the loss of protease inhibitor LEKTI, which leads to the dysregulation of epidermal proteases and severe skin-barrier defects. KLK5 was proposed as a major protease in NS pathology, however its inactivation is not sufficient to rescue the lethal phenotype of LEKTI-deficient mice. In this study, we further elucidated the in vivo roles of the epidermal proteases in NS using a set of mouse models individually or simultaneously deficient for KLK5 and KLK7 on the genetic background of a novel NS-mouse model. We show that although the ablation of KLK5 or KLK7 is not sufficient to rescue the lethal effect of LEKTI-deficiency simultaneous deficiency of both KLKs completely rescues the epidermal barrier and the postnatal lethality allowing mice to reach adulthood with fully functional skin and normal hair growth. We report that not only KLK5 but also KLK7 plays an important role in the inflammation and defective differentiation in NS and KLK7 activity is not solely dependent on activation by KLK5. Altogether, these findings show that unregulated activities of KLK5 and KLK7 are responsible for NS development and both proteases should become targets for NS therapy.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28095415 · DOI · PMC5283769
Physiological and Behavioural Characterisation of a Novel Steroid Sulfatase-Deficient Mouse [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Steroid sulfatase (STS) cleaves sulphate groups from steroid hormones.
- Closing excerpt
- The mechanistic basis of the associations described here requires further investigation, and whether these translate to humans remains to be tested.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (250 words)
Steroid sulfatase (STS) cleaves sulphate groups from steroid hormones. In humans, STS deficiency is associated with X-linked ichthyosis, an increased predisposition to neurodevelopmental and mood conditions (including Attention Deficit Hyperactivity Disorder, autism, depression and anxiety), and cardiac arrhythmia risk. Until recently, no single-gene 'knockout' mammalian model existed; previous work in such a model is limited to skin phenotypes. We generated a novel C57BL/6J mouse model with a deletion in exon 2 of Sts. We examined gene expression and enzyme activity in liver and brain samples of homozygous mice, and assessed the breeding performance and health of male and female deletion-carriers. Subsequently, we compared performance across a range of behavioural paradigms in wildtype and homozygous male and female mice: elevated plus maze, open field, rotarod, spontaneous alternation, and acoustic startle/prepulse inhibition. We also investigated serum steroid hormone levels by liquid chromatography-mass spectrometry and measured heart weights and two morphological indices (bodyweight/tibia length) post mortem. Homozygous mice almost completely lacked STS expression/activity. Genetically-altered mice exhibited grossly-normal breeding performance, health, and endocrinology. Homozygous mice were more active and had higher normalised heart weights than wildtype mice. We also found significant genotype × sex interactions on bodyweight and on two behavioural measures (potentially reflecting lower anxiety in homozygous males and heightened anxiety in homozygous females). The 'Sts-deletion' mouse represents an experimentally-tractable model in which to identify and characterise phenotypes associated with STS deficiency. The mechanistic basis of the associations described here requires further investigation, and whether these translate to humans remains to be tested.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42449517 · DOI · PMC13369296
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article One remarkable molecule: filaggrin [5]
- Research article Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders [6]
- Research article Netherton syndrome: skin inflammation and allergy by loss of protease inhibition [7]
- Research article Defects in the barrier [8]
- Research article Inherited ichthyosis: Non-syndromic forms [9]
- Research article Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment [10]
References
- Williams MR, Cau L, Wang Y, Kaul D, Sanford JA, Zaramela LS, et al.. Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome. . 2020. PMID 32130897 · DOI · PMC7183042
- Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome. . 2015. PMID 26390218 · DOI · PMC4577096
- Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, et al.. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype. . 2017. PMID 28095415 · DOI · PMC5283769
- Humby T, Shepherd FR, Elgie T, Anderson-Watkins L, Beevors LI, Taylor AE, et al.. Physiological and Behavioural Characterisation of a Novel Steroid Sulfatase-Deficient Mouse. . 2026. PMID 42449517 · DOI · PMC13369296
- Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012. PMID 22158554 · DOI · PMC3378480
- Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003. PMID 14572299 · DOI
- Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013. PMID 23344365 · DOI
- Roop D. Defects in the barrier. Science. 1995. PMID 7529942 · DOI
- Takeichi T, Akiyama M. Inherited ichthyosis: Non-syndromic forms. J Dermatol. 2016. PMID 26945532 · DOI
- Vahlquist A, Fischer J, Törmä H. Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2018. PMID 28815464 · DOI · PMC5797567
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.